ESR2 and cancer: Since ER-β is associated with decreased cancer proliferation and progression [49,51] and EE has an affinity for this receptor subtype [36], it can be assumed that the antiproliferative effect of EE that we noticed after the 24 h treatment might be the consequence of the EE-ER-β interaction.